

## RADIOPHARMA





## RADIOPHARMACEUTICALS

Radiopharmaceuticals Division has a solid foundation in developing, manufacturing and commercializing radiopharmaceuticals used for the diagnosis and treatment of various diseases.

Headquartered in Montreal, Canada this division has over 60-years of experience serving the global Nuclear Medicine community and the patients they serve.

The Radiopharmaceuticals Division employs over 170 highly skilled employees and is dedicated to providing high-quality radiopharmaceuticals and cutting-edge technologies to its customers. Backed by a global network of R&D facilities and staff, we are positioning ourselves to be the global leader in Nuclear Medicine by making significant investments in early- and late-stage product development.

The Division has strong partnerships and ongoing collaborations with the National Institute of Health (NIH), medical societies, regulatory agencies, and key opinion leaders across the globe in pursuit of its vision to Improve Lives Through Nuclear Medicine.

The U.S. Food and Drug Administration (FDA), Health Canada, International Organization for Standardization (ISO), Canadian Nuclear Safety Commission (CNSC) and Nuclear Regulatory Commission (NRC) regulate and certify the company's highly specialized manufacturing facility from a pharmaceutical, radioactive and device perspective.

We offer a broad portfolio of products which include diagnostic and therapeutic agents, as well as state-of-the-art devices, for cardiology, oncology, pulmonology, and endocrinology.

Our products are supplied to national commercial radiopharmacy networks, regional health systems, stand-alone imaging centers, and hospitals worldwide. The bedrock of the business are its lyophilized "cold kits", radioactive "hot products" and more recently a cutting edge cardiac PET tracer (Rb-82).

The Division continues to increase the range of product offerings in North America, while expanding into the Latin America, European and Asian markets through collaboration, contractual arrangements with partners and new distribution channels to drive growth in current and future products.

## Radiopharma

Jubilant Radiopharma is an industry-leading pharmaceutical company specializing in nuclear medicine. The company is focused on developing, manufacturing, commercializing and distributing high quality, sustainable diagnostic and therapeutic agents for the sole purpose of IMPROVING LIVES THROUGH NUCLEAR MEDICINE on a global scale.

Nearly a thousand strong and growing, the business consists of two distinct divisions; The Radiopharmaceuticals Division and the Radiopharmacies Division.



## RADIOPHARMACIES

Radiopharmacies Division is focused on compounding and distributing patient specific unit doses of radiopharmaceuticals and services to local Nuclear Medicine departments.

Headquartered in Orlando, Florida, this division has over 30-years of experience serving the U.S. Nuclear Medicine community and the patients they serve.

The Radiopharmacies Division operates a network of over 53 nuclear radiopharmacies across the United States and employs more than 700 highly skilled professionals. Three of these sites have on-site cyclotrons, used in the production of radiopharmaceuticals for Positron Emission Tomography (PET). Our U.S. pharmacy footprint is continually growing and our current geographical footprint serves nearly 4 million patients each year.

The highly trained team of skilled nuclear pharmacists and technologists deliver specialized expertise and customized solutions critical to supporting and enhancing the Nuclear Medicine industry in pursuit of its vision to Improve Lives Through Nuclear Medicine.

Our Radiopharmacies procures and supply only FDA inspected and accredited radiopharmaceutical products from cGMP compliant manufacturers and fully support USP compounding standards during compounding and dispensing. Additionally, in accordance with the State Boards of Pharmacy regulations, prescription orders are required for all radiopharmaceutical products dispensed.

We offer a wide spectrum of nuclear medicine products and services that provide safe and cost-effective ways to image the body and treat diseases.

Our radiopharmacies are open formulary, providing our customers with a full array of radiopharmaceutical product options. This allows clinicians to select the products they prefer to achieve the highest benefit for their patients. We deliver what they need, where they need it, when they need it.

The Division through its "Institute of Learning" is dedicated to advancing the field of Nuclear Medicine through education and sharing of innovative best practices. Through the Institute, the team creates a community of subject matter experts available to consult on clinical, technical, and regulatory matters.

## PRODUCT OFFERINGS

### Jubilant DraxImage Distribution Countries

(Approved & Marketed Products – Current Listing as on September 1, 2018)

#### USA

Drax Exametazime™

DRAXIMAGE® MAA

DRAXIMAGE® DTPA

DRAXIMAGE® I-131 Diagnostic Capsules

HICON® Sodium Iodine I 131 Solution USP

DRAXIMAGE® MDP-25

DRAXIMAGE® Sestamibi

SMART-FILL® Dispensing System

RUBY-FILL® (Rubidium Rb82 Generator & RUBY Rubidium Elution System)

#### CANADA

RUBY-FILL® (Rubidium Rb82 Generator)

RUBY Rubidium Elution System Device

DRAXIMAGE® MDP-25

DRAXIMAGE® MAA

DRAXIMAGE® DTPA

DRAXIMAGE® I-131 Diagnostic Capsules

DRAXIMAGE® I-131 Diagnostic Solution

DRAXIMAGE® I-131 Therapeutic Capsule

DRAXIMAGE® I-131 Therapeutic Solution

DRAXIMAGE® MDP-10

DRAXIMAGE® Sestamibi

DRAXIMAGE® Glucoptate

HICON® Sodium Iodine I 131 Solution USP

#### EUROPE

##### United Kingdom

DRAXIMAGE® Sestamibi (DRAXMIBI)

DRAXIMAGE® MDP-10

#### Netherlands

DRAXIMAGE® MDP-10

DRAXIMAGE® Sestamibi

#### Switzerland

RUBY-FILL® (Rubidium Rb82 Generator)

#### Luxembourg

RUBY-FILL® (Rubidium Rb82 Generator)

#### Germany

RUBY-FILL® (Rubidium Rb82 Generator)

#### ROW

##### Columbia

DRAXIMAGE® Sestamibi (pending)

DRAXIMAGE® MDP-10

HICON® Sodium Iodine I 131 Solution USP

##### Bermuda

DRAXIMAGE® I-131 Therapeutic Capsule

DRAXIMAGE® DTPA

DRAXIMAGE® MAA

##### Barbados

DRAXIMAGE® DTPA

##### Jamaica

DRAXIMAGE® DTPA

DRAXIMAGE® Sestamibi

DRAXIMAGE® Glucoptate

DRAXIMAGE® MDP-10

DRAXIMAGE® I-131 Therapeutic Solution

##### Trinidad & Tobago

DRAXIMAGE® I-131 Therapeutic Solution

DRAXIMAGE® I-131 Therapeutic Capsule

DRAXIMAGE® MDP-10

## Venezuela

HICON® Sodium Iodine I 131 Solution USP

## Cayman Islands

DRAXIMAGE® I-131 Diagnostic Solution

DRAXIMAGE® MAA

## Costa Rica

DRAXIMAGE® I-131 Therapeutic Solution

DRAXIMAGE® I-131 Therapeutic Capsule

## New Zealand

DRAXIMAGE® MDP-10

DRAXIMAGE® MAA

DRAXIMAGE® DTPA

## Israel

DRAXIMAGE® MDP-10

DRAXIMAGE® MAA

DRAXIMAGE® DTPA

## Philippines

DRAXIMAGE® MDP-10

DRAXIMAGE® MAA

DRAXIMAGE® DTPA

## KSA

DRAXIMAGE® MDP-10

DRAXIMAGE® DTPA

DRAXIMAGE® Sestamibi

DRAXIMAGE® Gluceptate

## India

DRAXIMAGE® Sestamibi

## State of the Art Facility

3 Hot Cells

1 Isolator

1 Automated Loading Station

4 Semi-Automated Loading Stations

Packaging Station

## Regulatory and Quality Approvals:

ISO 13485:2016

ISO CE Mark Certified

Health Canada

US-FDA (Inspected/Accredited)

CNSC (Canadian Nuclear Safety Commission)

NRC (US Nuclear Regulatory Commission)



## Product Portfolio For Your Diagnostic & Therapeutic Needs

### Brain Imaging

- DTPA and Gluceptate

### Cardiac PET Imaging

- RUBY-FILL®

### Kidney Imaging

- DTPA and Gluceptate

### Bone Imaging

- MDP

### Thyroid Therapy

- I-131 Iodine and HICON®

### Cardiac SPECT Imaging

- Sestamibi

### Functional Lung Imaging

- MAA and DTPA

### Leukocyte Labeling

- Exametazime



### Jubilant DraxImage, Inc.

16751, Trans-Canada Highway,  
Kirkland (Montreal), Québec, Canada H9H 4J4  
Tel : 1-800-361-2356 or +514-694-8220

Our offices are open Monday to Friday from 8:00 AM to 5:00 PM Eastern Time

For business inquiries e-mail: [customerservice@jdi.jubl.com](mailto:customerservice@jdi.jubl.com)  
[www.draximage.com](http://www.draximage.com)

